Adenoma Detection Rates by Physicians and Subsequent Colorectal Cancer Risk
This observational study investigates the association of adenoma detection rates among physicians who perform colonoscopy and postcolonoscopy colorectal cancer incidence.
Related Articles
Balancing cancer care and holiday expectations
Social workers at Fox Chase Cancer Center share tips for managing what everyone hopes for and what’s possible for the patient.
View From the Other Side of the Stethoscope: Simone Biles’… : Oncology Times
An abstract is unavailable.
The 2024 Presidential Election—An Inflection Point for Science
This JAMA Forum discusses the erosion of public trust in science during the COVID-19 pandemic and provides ideas for improving scientific literacy and communication to…
The Limited Value of Multivitamin Supplements
With as many as 1 in 3 US adults using multivitamin supplements, the question as to whether these supplements reduce mortality is an important public…
Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
The 2024 Presidential Election—An Inflection Point for Science
This JAMA Forum discusses the erosion of public trust in science during the COVID-19 pandemic and provides ideas for improving scientific literacy and communication to…
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Less Common Molecular Alterations in pLGG and Testing Recommendations
The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for…
Government Funding for the Development of Enzalutamide
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Durvalumab Shows Few High-Grade AEs in Cutaneous T-Cell Lymphoma
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
